“We are pleased that one of our applications has been allowed by the U.S. Patent Office and we are encouraged to continue our systematic work to protect our rights”, said CSO Dr. Anna-Karin Maltais. 

“This notice of allowance, in the world´s biggest pharmaceutical market, strengthens us in our discussions with potential partners and in our further development of Immunose™ FLU“, said CEO Dr. Hans Arwidsson.

This information is information that Eurocine Vaccines AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 24th 2017.